Inflammation is a component of most ocular diseases. Aside from trauma, inflammatory ocular diseases, in aggregate, are the leading cause of blindness worldwide. Aldeyra is currently developing ophthalmic solutions for the treatment of several ocular inflammatory diseases including:
Dry Eye Disease
Dry eye disease is a sub-optimally treated chronic condition that affects 20 million patients in the United States.
Allergic Conjunctivitis
Allergic conjunctivitis is a persistently disturbing disease, characterized by ocular itching, that is not effectively treated in approximately 30 million patients in the United States.
Proliferative Vitreoretinopathy
Proliferative vitreoretinopathy is a rare blinding disease, for which no therapy is available, that occurs following retinal detachment.
In addition, Aldeyra is developing product candidates for the treatment of other forms of retinal inflammation, potentially including dry age-related macular degeneration, Stargardt disease, geographic atrophy, diabetic macular edema, diabetic retinopathy, posterior uveitis, and retinal vein occlusion.